Published in BMC Infect Dis on October 13, 2016
Prosthetic-joint infections. N Engl J Med (2004) 12.71
Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrob Agents Chemother (1990) 3.38
Proceedings of the International Consensus on Periprosthetic Joint Infection. Bone Joint J (2013) 2.72
A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis (2012) 2.46
Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2013) 2.22
Characteristics of prosthetic joint infections due to Enterococcus sp. and predictors of failure: a multi-national study. Clin Microbiol Infect (2014) 2.02
Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother (1994) 1.89
Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis (2011) 1.87
Outcome of penicillin-susceptible streptococcal prosthetic joint infection treated with debridement and retention of the prosthesis. Clin Infect Dis (2003) 1.33
Irrigation and debridement for periprosthetic infections: does the organism matter? J Arthroplasty (2011) 1.13
Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev (2010) 1.12
Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis (2010) 1.04
Pathogen-driven decision for implant retention in the management of infected total knee prostheses. Int Orthop (2013) 0.98
The preoperative prediction of success following irrigation and debridement with polyethylene exchange for hip and knee prosthetic joint infections. J Arthroplasty (2012) 0.97
Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy (1998) 0.97
Outcome of group B streptococcal prosthetic hip infections compared to that of other bacterial infections. Joint Bone Spine (2009) 0.92
Increased risk of joint failure in hip prostheses infected with Staphylococcus aureus treated with debridement, antibiotics and implant retention compared to Streptococcus. Int Orthop (2014) 0.91
Group B streptococcus in prosthetic hip and knee joint-associated infections. J Hosp Infect (2011) 0.89
Successful antimicrobial therapy and implant retention for streptococcal infection of prosthetic joints. ANZ J Surg (2004) 0.88
Acute haematogenous prosthetic joint infection: prospective evaluation of medical and surgical management. Clin Microbiol Infect (2010) 0.88
[Recommendations for clinical practice. Osteo-articular infection therapy according to materials used (prosthesis, implants, osteosynthesis)]. Med Mal Infect (2009) 0.82
Efficacy of debridement in hematogenous and early post-surgical prosthetic joint infections. Int J Artif Organs (2011) 0.82
[Diffusion in bone tissue of antibiotics]. Presse Med (2000) 0.82
Antibacterial activity of various antibiotics against oral streptococci isolated in the oral cavity. Int J Immunopathol Pharmacol (2012) 0.81
[Prosthetic joint infection: new developments in diagnosis and treatment]. Dtsch Med Wochenschr (2013) 0.80
Effectiveness of ciprofloxacin or linezolid in combination with rifampicin against Enterococcus faecalis in biofilms. J Antimicrob Chemother (2011) 0.80
Influence of daily dosage and frequency of administration of rifampicin-levofloxacin therapy on tolerance and effectiveness in 154 patients treated for prosthetic joint infections. Eur J Clin Microbiol Infect Dis (2015) 0.79
Group B streptococcal prosthetic joint infections. J South Orthop Assoc (2001) 0.77